PBMC Humanized Mouse Models

PBMC humanized mouse models are immunodeficient mice reconstituted with human peripheral blood mononuclear cells from an adult donor. Human T cells engraft rapidly and reach functional numbers within days to a small number of weeks, which makes this the fastest route from study initiation to an immune-competent readout.

The platform is defined as much by its time limit as by its speed. Human T cells recognize murine major histocompatibility complex as foreign, and the resulting xenogeneic graft-versus-host disease develops within weeks of engraftment. That window is a hard constraint on study duration rather than a complication to be managed, and a study designed without accounting for it will lose animals to graft-versus-host disease before the tumor endpoint is reached.

Altogen Labs conducts PBMC humanized studies in an IACUC-regulated facility with reconstitution verified by flow cytometry before animals enter treatment, and with graft-versus-host disease monitoring running alongside tumor endpoints throughout. To discuss whether the available window fits a mechanism, request a quote.

What the platform supports

PBMC models are appropriate where the mechanism depends on mature human T cells and where the therapeutic effect is expected to be apparent within a short treatment period. This covers CD3-engaging bispecific antibodies, adoptive transfer of expanded T cells including tumor-infiltrating lymphocytes, CAR-T cell products where rapid activity is anticipated, and checkpoint inhibitors acting directly on T cells.

What the platform does not support is equally important. Reconstitution is dominated by T cells, with natural killer cells, B cells, and myeloid lineages poorly represented. A mechanism that requires antigen presentation by human dendritic cells, antibody-dependent cellular cytotoxicity through human natural killer cells, or myeloid-mediated suppression will not be adequately modeled here. Where those lineages matter, CD34-positive reconstitution or the ATO-supported BLT platform is the appropriate alternative.

Donor considerations

Donor selection is a design variable rather than an administrative step. Donors differ in T-cell composition, activation state, and the rate at which graft-versus-host disease develops, and that variability propagates directly into study outcomes. Studies are designed with donor as a controlled factor: a single donor across all arms where the comparison is between treatments, or multiple donors where the question concerns generalizability of response. Cohort sizing accounts for the additional variance that donor-derived material introduces relative to conventional xenograft work.

Study design within the window

Because the experimental window is short, sequencing matters. Tumor implantation, reconstitution, and treatment initiation are scheduled so that the treatment period falls inside the period of stable reconstitution and before graft-versus-host disease becomes clinically significant. Reconstitution is confirmed by flow cytometry against defined thresholds before randomization, so treatment groups are comparable in immune status as well as tumor burden.

Endpoints are selected for a compressed timeframe. Tumor volume and growth inhibition remain the primary readouts, with survival used cautiously since animals may reach a welfare endpoint from graft-versus-host disease rather than from tumor progression, and the two must be distinguished in the analysis rather than pooled.

Applied examples

Bispecific antibody activity. A CD3-engaging bispecific is administered to tumor-bearing PBMC humanized mice, with tumor growth inhibition measured alongside cytokine release, establishing both activity and the cytokine profile associated with it within a single short study.

Adoptive T-cell transfer. Expanded T cells are transferred into tumor-bearing animals, with tumor response followed and transferred cell persistence tracked in blood across the treatment period.

Rapid checkpoint screen. Two checkpoint antibodies are compared head to head in a matched design, using the short window deliberately to obtain a comparative signal quickly before committing to a longer CD34-positive study.

Welfare monitoring and study conduct

All procedures are conducted under active IACUC protocols. Graft-versus-host disease is an expected feature of this model rather than an adverse event, so protocols specify clinical scoring criteria, monitoring frequency, and the specific signs that trigger removal from study, and monitoring intensifies as the study progresses. Human cells are commercially obtained from suppliers maintaining donor eligibility documentation. Reconstitution thresholds, treatment window, and endpoint criteria are defined before initiation. GLP standards are applied where a study is formally designated as GLP.

Send mechanism, expected time to effect, and study objectives, or request a quote.